The use of siRNA silencing in the prevention of metastasis

Details for Australian Patent Application No. 2004284013 (hide)

Owner Prydz, H. Holen, T. Amarzguioui, M.

Inventors Amarzguioui, Mohammed; Holen, Torgeir; Prydz, Hans

Agent Davies Collison Cave

Pub. Number AU-A-2004284013

PCT Pub. Number WO2005/040187

Priority 60/497,314 25.08.03 US; 2003 3492 06.08.03 NO

Filing date 5 August 2004

Wipo publication date 6 May 2005

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

A61P 35/04 (2006.01) Antineoplastic agents

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Event Publications

23 March 2006 PCT application entered the National Phase

  PCT publication WO2005/040187 Priority application(s): WO2005/040187

23 August 2007 Assignment before Grant

  Amarzguioui, Mohammed; Holen, Torgeir; Prydz, Hans The application has been assigned to siRNAsense AS

28 April 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004284015-A tool for connection and disconnection of cargo

2004284012-Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors